Citi has just upgraded CSL Limited (ASX:CSL) to "buy"

The share price of market darling CSL Limited (ASX: CSL) will end the week in the red but the stock has fallen to a point where Citigroup thinks its too attractive to ignore.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share price of market darling CSL Limited (ASX: CSL) will end the week in the red but the stock has fallen to a point where Citigroup thinks it's too attractive to ignore.

Shares in the blood products maker tumbled 0.9% in after lunch trade to $187.07 as the S&P/ASX 200 (Index:^AXJO) (ASX: XJO) index inched 0.2% lower.

But CSL isn't alone in the doldrums. It's peers Cochlear Limited (ASX: COH), RESMED/IDR UNRESTR (ASX: RMD) and Nanosonics Ltd. (ASX: NAN) are also underperforming.

Citigroup thinks the dip is a buying opportunity for CSL and it's upgraded its recommendation to "buy" from "hold" after watching the stock tumble 19% since the start of September.

"Predominantly, we believe this reflects an increase in the US 10-year bond rate, and a commensurate sell off on highly rated, long duration companies," said the broker.

The spike in the 10-year yield has been blamed for a global sell-off in growth stocks that are trading at a premium to the market.

While there is a fundamental reason for the yield and stock valuations to move in opposite directions, the big fall in CSL's shares is an over-reaction if Citi's calculations are on the money.

"Since the beginning of September, the US 10 bond has increased by ~50bp [basis points] or 10%. As a result of this material move, we have updated our DCF [discounted cash flow] valuation," said Citi.

"Our WACC [weighted average cost of capital] moves from 6.8% to 7.1%. As a result, our valuation and target price move to A$218 from A$238."

Investors can also take heart that there were no negative surprises at CSL's annual general meeting (AGM) yesterday. The company reiterated its FY19 guidance in constant currency terms although it did highlight the negative impact from the exchange rate, which will trim around US$60 million off its net profit for this financial year.

Consensus is forecasting an FY19 net profit of US$1.96 billion and Citi is a little ahead of consensus with a US$1.99 billion estimate.

One longer-term risk to CSL is a potential new treatment for a rare autoimmune disease called primary immune thrombocytopenia (PIT).

The new treatment could displace the need for Intravenous immunoglobulin (IVIg) in the treatment of PIT. CSL (among others) makes IVIg and could be affected by this new discovery.

However, this new treatment might take years to be commercialised as it is only just starting Phase II trials.

CSL isn't the only blue-chip stock that should be on your watchlist. The experts at the Motley Fool have picked three of their best blue-chip stock ideas for FY19 and you can find out what they are by following the free link below.

Motley Fool contributor BrenLau has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »